News Sentiment

RCKT sentiment intelligence

Rocket Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.44 Week of 17 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

-12.0% over one week, +2.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Rocket Pharmaceuticals stock steadies as gene therapy pipeline advances and cash runway extends

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -12.0% Price reacting lower
Trend fit Trend inactive 2.7% over four weeks
Fair value -72.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 46
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 14
Market source 13
Stock Titan 12
simplywall.st 5
The National Law Review 3
www.marketscreener.com 3
MT Newswires 2
Ad-hoc-news.de 1

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 15
Regulatory and legal 6
Analyst action 3
Deals and strategy 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
Ad-hoc-news.de Direct company coverage

Rocket Pharmaceuticals stock steadies as gene therapy pipeline advances and cash runway extends

Rocket Pharmaceuticals (RCKT) stock is gaining investor interest due to its advancing gene therapy pipeline and an extended cash runway, which supports trials into 2027. Despite reporting operating losses, the company modestly beat analyst expectations, and its Danon disease gene

Tone
Positive 70/100
Event
Analyst action
Published
22 Jul 2026 22:05
Source
Ad-hoc-news.de
TradingView Direct company coverage

ETFs Investing in Rocket Pharmaceuticals, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Rocket Pharmaceuticals, Inc. (9IP1). It provides a detailed table including each ETF's market value, weight of Rocket Pharmaceuticals in the fund, issuer, management style, expense ratio, assets under man

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 21:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. – DUS:9IP1

This article provides financial information for Rocket Pharmaceuticals, Inc. (DUS:9IP1) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed with no trades at the time of publication. The page i

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 03:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW

This article displays the "Enterprise value to revenue forward" metric for Rocket Pharmaceuticals, Inc., publicly traded under the NASDAQ:RCKTW symbol. The content provides a basic financial overview for investors and traders on TradingView. The presented value focuses on the for

Tone
Neutral 50/100
Event
Earnings
Published
19 Jul 2026 16:39
Source
TradingView
Stock Titan Direct company coverage

RCKTW SEC Filings - ROCKET PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms

This page provides access to ROCKET PHARMACEUTICALS INC SEC filings (Ticker: RCKTW), including 10-K, 10-Q, 8-K, and insider trading forms. It features AI-generated summaries, sentiment and impact scores, and corresponding end-of-day stock performance. Recent filings include Form

Tone
Neutral 50/100
Event
Market update
Published
18 Jul 2026 08:09
Source
Stock Titan
Stock Titan Direct company coverage

Rocket Pharmaceuticals (RCKT) accounting chief reports 52,576-share RSU stake

Rocket Pharmaceuticals (RCKT) Principal Accounting Officer, Joseph Manhede, has reported an initial equity stake of 52,576 restricted stock units (RSUs) in the company. These RSUs will convert to common stock on a one-for-one basis, with one-third vesting on May 4, 2027, and the

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 23:11
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW

This article focuses on the "Price to book forward" metric for Rocket Pharmaceuticals, Inc., traded on NASDAQ under the symbol RCKTW. The content is presented within the TradingView platform, emphasizing financial data and market analysis for the company.

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 22:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW

This article provides financial information for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKTW), specifically focusing on its forward price-to-earnings ratio. The content appears to be a financial data page from TradingView, displaying the stock's market status and offering various

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 09:10
Source
TradingView
Stock Titan Direct company coverage

[144] ROCKET PHARMACEUTICALS, INC. SEC Filing

This article reports on a recent SEC Form 144 filing by ROCKET PHARMACEUTICALS, INC. (RCKT) concerning the proposed sale of securities. The filing details the sale of 10,670 shares of common stock with an aggregate market value of $41,393.20 by an unnamed person through Fidelity

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 19:14
Source
Stock Titan
Stock Titan Direct company coverage

Equity awards to Rocket Pharmaceuticals (RCKT) director detailed in Form 4

Rocket Pharmaceuticals (RCKT) director Mikael Dolsten received routine equity compensation awards, including 22,862 restricted stock units (RSUs) and 64,860 stock options. These awards are compensation-related acquisitions, not open-market trades. Both the RSUs and options fully

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 08:39
Source
Stock Titan
TradingView Direct company coverage

Number of shareholders of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW

This article provides access to the number of shareholders for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKTW). It indicates that the specific shareholder data is available under the "Financials" section on TradingView. The page highlights that the market was closed and no trades we

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 03:39
Source
TradingView
Stock Titan Direct company coverage

Equity awards granted to RCKT director and 10% owner Roderick Wong

Rocket Pharmaceuticals (RCKT) director and 10% owner Roderick Wong has been granted new equity awards, including 27,832 restricted stock units (RSUs) and an option to purchase 78,960 shares of common stock. Both the RSUs and stock options will vest fully on June 18, 2027, with th

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 23:39
Source
Stock Titan
Stock Titan Direct company coverage

Director at Rocket Pharmaceuticals (RCKT) receives RSU and stock option grants

Carsten Boess, a director at Rocket Pharmaceuticals (RCKT), has received significant stock-based compensation, including 22,862 restricted stock units (RSUs) and options for 64,860 shares of common stock. Both the RSUs and stock options will fully vest on June 18, 2027, with the

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 23:39
Source
Stock Titan
Stock Titan Direct company coverage

Director at Rocket Pharmaceuticals (RCKT) receives RSUs and stock options

Rocket Pharmaceuticals (RCKT) director Fady Ibraham Malik has reported receiving equity awards, including 22,862 restricted stock units (RSUs) and stock options for 64,860 shares. Both the RSUs and stock options will vest in full on June 18, 2027, with the stock options having an

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 23:39
Source
Stock Titan
The National Law Review Direct company coverage

Securities Lawsuit Alert: Rocket Pharmaceuticals, Inc. (RCKT) - Contact Levi & Korsinsky Before August 11, 2025

Levi & Korsinsky, LLP has announced a securities lawsuit alert for investors of Rocket Pharmaceuticals, Inc. (RCKT). Shareholders who suffered losses between February 27, 2025, and May 26, 2025, are encouraged to contact the firm by August 11, 2025, as the company is accused of m

Tone
Negative 14/100
Event
Regulatory and legal
Published
05 Jul 2026 19:41
Source
The National Law Review
TradingView Direct company coverage

Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. – SWB:9IP1

This article provides financial information for Rocket Pharmaceuticals, Inc. (SWB:9IP1), specifically its enterprise value to EBITDA forward. It notes that the market is currently closed with no trades. The data is provided by ICE Data Services and FactSet.

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 05:40
Source
TradingView
TradingView Direct company coverage

Rocket Pharmaceuticals, Inc. Warrant 2023- on Rocket Pharmctc Financial Disclosures & SEC Filings

This article provides a comprehensive list of financial disclosures and SEC filings for Rocket Pharmaceuticals, Inc. (RCKTW), detailing various corporate events such as earnings reports, FDA announcements, and conference presentations spanning from 2024 to 2026. Key advancements

Tone
Positive 73/100
Event
Earnings
Published
02 Jul 2026 19:09
Source
TradingView
Stock Titan Direct company coverage

Rocket Pharmaceuticals (NASDAQ: RCKT) appoints new Principal Accounting Officer

Rocket Pharmaceuticals (NASDAQ: RCKT) has announced a change in its Principal Accounting Officer. John Militello resigned, effective July 7, 2026, and Joseph Manhede, currently Associate Vice President, Corporate Controller, will assume the role on July 8, 2026. Manhede, a CPA wi

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:09
Source
Stock Titan
Minichart Direct company coverage

Rocket Pharmaceuticals Appoints Joseph Manhede as Principal Accounting Officer – SEC 8-K Filing June 2026

Rocket Pharmaceuticals (NASDAQ: RCKT) has announced significant leadership changes in its finance department. John Militello, VP of Finance and Principal Accounting Officer, has resigned, with his departure effective July 7, 2026. Joseph Manhede, who joined the company in April 2

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 07:01
Source
Minichart
www.marketscreener.com Direct company coverage

Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2500 Growth Benchmark

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) has been dropped from the Russell 2500 Growth Benchmark, as well as several other Russell indices including the Small Cap Comp Growth, 2000 Growth, and 3000E Growth benchmarks. Concurrently, the company was added to the Russell 3000E I

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 19:34
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) added to Russell Microcap Value Benchmark Index

Rocket Pharmaceuticals, Inc. (RCKT) has been added to the Russell Microcap Value Benchmark Index. This news follows several other index adjustments, including being dropped from the Russell 2000 Growth and Russell 3000E Growth benchmarks, but added to the broader Russell 3000E In

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 13:13
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2000 Growth Benchmark

Rocket Pharmaceuticals, Inc. (RCKT) has been dropped from the Russell 2000 Growth Benchmark. This news comes alongside other recent index adjustments, including being added to the Russell Microcap Value Benchmark Index and the Russell 3000E Index, while also being dropped from th

Tone
Negative 36/100
Event
Market update
Published
29 Jun 2026 11:13
Source
www.marketscreener.com
TradingView Direct company coverage

Price to earnings forward of Rocket Pharmaceuticals, Inc. – BOATS:RCKTW

This article provides financial data for Rocket Pharmaceuticals, Inc. (RCKTW), specifically focusing on its forward price-to-earnings ratio. It indicates current valuation metrics within the Health Technology and Biotechnology sectors, as presented on the TradingView platform. Th

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 04:40
Source
TradingView
The National Law Review Direct company coverage

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action

Levi & Korsinsky LLP has filed a class action securities lawsuit against Rocket Pharmaceuticals, Inc. (RCKT) to recover losses for shareholders affected by alleged securities fraud between September 17, 2024, and May 26, 2025. The lawsuit claims Rocket Pharmaceuticals made mislea

Tone
Negative 20/100
Event
Regulatory and legal
Published
28 Jun 2026 04:40
Source
The National Law Review
The National Law Review Direct company coverage

Rocket Pharmaceuticals, Inc. (RCKT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before August 11, 2025

Levi & Korsinsky LLP has filed a class action securities lawsuit against Rocket Pharmaceuticals, Inc. (RCKT), urging investors who suffered losses between February 27, 2025, and May 26, 2025, to contact them before August 11, 2025. The lawsuit alleges that Rocket made misleading

Tone
Negative 9/100
Event
Regulatory and legal
Published
28 Jun 2026 04:09
Source
The National Law Review
TradingView Direct company coverage

Price to sales forward of Rocket Pharmaceuticals, Inc. – BOATS:RCKTW

This article provides a brief financial snippet for Rocket Pharmaceuticals, Inc. under the ticker RCKTW, specifically focusing on its forward price-to-sales ratio. The content is sparse, indicating no active trades and only displaying the stock's name and its listing on the Blue

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 08:09
Source
TradingView